RE:RE:RE:RE:RE:RE:RE:RE:General question for the boardI think the low number of treatments could be the decisive factor in the acceptance of Ruvidar PDT by urologists, especially if the efficacy, safety and price point are competitive (which they look like they will be). Ruvidar could become the "go to" treatment - the "once and done" option. If it works great, if not then they can try one of the more expensive, treatment-burdensome options. One lesson from the trials is that if a patient does not have a CR at 90 days, or recurs at any point up to 450 days then there isn't much chance for a longer term response. If, however, a patient gets to 450 days with a CR they may be out of the woods. At that point it looks very much like a cure.
If the NMIBC Ruvidat treatment is accepted, all bets are off. There could be any number of trials initiated with Ruvidar by itself or in combo treatments for various cancer indications and even head to head against BCG as a primary treatment for NMIBC alone or in combination with another drug. Numerous cancer trials could also begin of Rutherrin activated by other drugs, radiation and visible light.